A study in the journal Antimicrobial Agents and Chemotherapy, by Dr. Yen T. Duong from University of California - Davis and colleagues, reports the small-molecule entry inhibitor DCM205 binds to an HIV-1 envelope glycoprotein and directly inactivates the virus.
DCM205 potently and selectively inhibits HIV-1 NL4-3 and blocks an early stage of the replication cycle. They also investigated the ability of DCM205 to interfere with HIV-1 infectivity in vitro.
DCM205 bound tightly, and apparently irreversibly, to the HIV-1 envelope glycoprotein gp120, preventing the infectivity of HIV-1.
"DCM205 is a prototype for a new class of small-molecule entry inhibitors that can disarm HIV-1 by direct inactivation through a specific interaction with gp120 without the presence of a cellular target," the authors conclude. "These characteristics make this approach particularly promising for the development of DCM205 as a topical microbicide."
Direct Inactivation of Human Immunodeficiency Virus Type 1 by a Novel Small-Molecule Entry Inhibitor, DCM205
Yen T. Duong et al
Antimicrobial Agents and Chemotherapy, May 2007, p. 1780-1786, Vol. 51, No. 5
Link to Reuter’s Report via Medscape [registration required]